Skip to content
Home/Research/Adipotide (FTPP)

Adipotide (FTPP) Research & Studies

We track 8 published, PubMed-indexed studies for Adipotide (FTPP), spanning 2011 to 2022. The research below includes 7 research articles, 1 clinical trial.

These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
7
Research Articles
1
Clinical Trial

Fatty Liver/Adipose Tissue Dual-Targeting Nanoparticles with Heme Oxygenase-1 Inducer for Amelioration of Obesity, Obesity-Induced Type 2 Diabetes, and Steatohepatitis.

Research Article
Hong J, Kim YH|Adv Sci (Weinh)|2022

Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes.

Research Article
Sharma G, Hu C, et al.|Sci Transl Med|2020

Epigenetic Age Acceleration in Adolescence Associates With BMI, Inflammation, and Risk Score for Middle Age Cardiovascular Disease.

Research Article
Huang RC, Lillycrop KA, et al.|J Clin Endocrinol Metab|2019

Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.

Clinical Trial
Preiss D, Dawed A, et al.|Diabetes Obes Metab|2017

A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication.

Research Article
Hossen N, Kajimoto K, et al.|J Control Release|2013

Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys".

Research Article
Criscione L|Sci Transl Med|2012

Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium.

Research Article
Kim DH, Sartor MA, et al.|Diabetes|2012

A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.

Research Article
Barnhart KF, Christianson DR, et al.|Sci Transl Med|2011